Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,206 questions in 117 reviews · Common Mental Disorders
current versionsNo studies 387 · 17.5%Ungraded 111 · 5%Very low 635 · 28.8%Low 568 · 25.7%Moderate 449 · 20.4%High 56 · 2.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Psychological therapy vs any comparator Functioning short‐term · anxiety and depression in children and adolescents with long‐term physical conditions Psychological therapies for anxiety and depression in children and adolescents with long‐term physical… (2018) · Cochrane | no estimate extracted | 7 studies · 483 participants | Low |
Psychological therapy vs any comparator Status of long‐term physical condition short‐term · anxiety and depression in children and adolescents with long‐term physical conditions Psychological therapies for anxiety and depression in children and adolescents with long‐term physical… (2018) · Cochrane | no estimate extracted | 14 studies · 823 participants | Low |
Psychological therapy vs any comparator Dropouts due to adverse events · anxiety and depression in children and adolescents with long‐term physical conditions Psychological therapies for anxiety and depression in children and adolescents with long‐term physical… (2018) · Cochrane | no estimate extracted | NR | No studies |
Psychological therapy vs any comparator Suicide‐related behaviour · anxiety and depression in children and adolescents with long‐term physical conditions Psychological therapies for anxiety and depression in children and adolescents with long‐term physical… (2018) · Cochrane | no estimate extracted | NR | No studies |
EHealth interventions vs any comparator Depression (postintervention) · children and adolescents, aged 10 to 18 years, with long‐term physical conditions E‐Health interventions for anxiety and depression in children and adolescents with long‐term physical… (2018) · Cochrane | no estimate extracted | 5 studies · 441 participants | Very low |
EHealth interventions vs any comparator Anxiety (postintervention) · children and adolescents, aged 10 to 18 years, with long‐term physical conditions E‐Health interventions for anxiety and depression in children and adolescents with long‐term physical… (2018) · Cochrane | no estimate extracted | 2 studies · 324 participants | Very low |
EHealth interventions vs any comparator Treatment acceptability (postintervention) · children and adolescents, aged 10 to 18 years, with long‐term physical conditions E‐Health interventions for anxiety and depression in children and adolescents with long‐term physical… (2018) · Cochrane | no estimate extracted | 2 studies · 304 participants | Very low |
EHealth interventions vs any comparator Quality of life (postintervention) · children and adolescents, aged 10 to 18 years, with long‐term physical conditions E‐Health interventions for anxiety and depression in children and adolescents with long‐term physical… (2018) · Cochrane | no estimate extracted | 1 study · 34 participants | Very low |
EHealth interventions vs any comparator Functioning (postintervention) · children and adolescents, aged 10 to 18 years, with long‐term physical conditions E‐Health interventions for anxiety and depression in children and adolescents with long‐term physical… (2018) · Cochrane | no estimate extracted | 3 studies · 368 participants | Very low |
EHealth interventions vs any comparator Status of long‐term physical condition (postintervention) · children and adolescents, aged 10 to 18 years, with long‐term physical conditions E‐Health interventions for anxiety and depression in children and adolescents with long‐term physical… (2018) · Cochrane | no estimate extracted | 5 studies · 463 participants | Low |
Comparison 1: 5HT1A partial agonists vs placebo Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 1 [0.07, 14.55] | 1 study · 30 participants | Very low |
Comparison 3: anticonvulsant levetiracetam vs placebo Dropouts due to adverse events (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 2 [0.81, 4.94] | 2 studies · 235 participants | Very low |
Comparison 3: anticonvulsant levetiracetam vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 2 studies · 228 participants | Very low |
Comparison 3: anticonvulsant levetiracetam vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 16 participants | Very low |
Comparison 3: anticonvulsant levetiracetam vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 16 participants | Very low |
Comparison 4: antipsychotics vs placebo Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 7 [0.45, 108.26] | 1 study · 10 participants | Very low |
Comparison 4: antipsychotics vs placebo Dropouts due to adverse events (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 0.71 [0.06, 8.9] | 1 study · 12 participants | Very low |
Comparison 4: antipsychotics vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 9 participants | Very low |
Comparison 5: benzodiazepines vs placebo Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 4.03 [2.45, 6.65] | 2 studies · 132 participants | Low |
Comparison 5: benzodiazepines vs placebo Relapse rate ‐ no. relapsed · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 0.12 [0.01, 2.14] | 1 study · 36 participants | Low |
Comparison 5: benzodiazepines vs placebo Dropouts due to adverse events (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 1.68 [0.21, 13.13] | 2 studies · 96 participants | Very low |
Comparison 1: 5HT1A partial agonists vs placebo Dropouts due to adverse events (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 3 [0.13, 68.26] | 1 study · 30 participants | Very low |
Comparison 5: benzodiazepines vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 2 studies · 135 participants | Very low |
Comparison 5: benzodiazepines vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 75 participants | Low |
Comparison 5: benzodiazepines vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 75 participants | Low |
Comparison 6: beta‐blockers vs placebo Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 1.09 [0.63, 1.88] | 2 studies · 97 participants | Very low |
Comparison 7: MAOIs vs placebo Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 2.36 [1.48, 3.75] | 4 studies · 235 participants | Low |
Comparison 7: MAOIs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 4 studies · 218 participants | Very low |
Comparison 7: MAOIs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 51 participants | Very low |
Comparison 7: MAOIs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 51 participants | Very low |
Comparison 7: MAOIs vs placebo Clinical Global Impressions scale change item (CGI‐I):no. of responders (long term) Post‐treatment: 6 months · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 1.84 [1.02, 3.33] | 2 studies · 113 participants | Very low |
Comparison 8: NARIs vs placebo Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 0.7 [0.19, 2.54] | 1 study · 27 participants | Very low |
Comparison 1: 5HT1A partial agonists vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |
Comparison 8: NARIs vs placebo Dropouts due to adverse events (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 2.8 [0.12, 63.2] | 1 study · 27 participants | Very low |
Comparison 8: NARIs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 26 participants | Very low |
Comparison 9: NaSSAs vs placebo Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 1 [0.28, 3.63] | 1 study · 60 participants | Very low |
Comparison 9: NaSSAs vs placebo Dropouts due to adverse events (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 5 [0.25, 99.95] | 1 study · 60 participants | Very low |
Comparison 9: NaSSAs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 2 studies · 126 participants | Very low |
Comparison 9: NaSSAs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 60 participants | Low |
Comparison 9: NaSSAs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 60 participants | Low |
Comparison 10: RIMAs vs placebo Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 1.83 [1.32, 2.55] | 8 studies · 1270 participants | Low |
Comparison 10: RIMAs vs placebo Dropouts due to adverse events (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 1.42 [0.86, 2.34] | 8 studies · 1305 participants | Very low |
Comparison 10: RIMAs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 6 studies · 1163 participants | Very low |
Comparison 2: anticonvulsants/GABAs vs placebo Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 1.6 [1.16, 2.2] | 3 studies · 532 participants | Moderate |
Comparison 10: RIMAs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 5 studies · 695 participants | Low |
Comparison 10: RIMAs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 6 studies · 724 participants | Very low |
Comparison 10: RIMAs vs placebo Clinical Global Impressions scale change item (CGI‐I): no. of responders (long term) Post‐treatment: 1‐15 months · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 1.5 [1.12, 2] | 1 study · 90 participants | Moderate |
Comparison 11: SARIs vs placebo Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | no estimate extracted | 1 study · 102 participants | Very low |
Comparison 12: SNRIs vs placebo Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 1.3 [0.85, 1.99] | 4 studies · 1173 participants | Low |
Comparison 12: SNRIs vs placebo Dropouts due to adverse events (acute phase) · adults with SAnD Pharmacotherapy for social anxiety disorder (SAnD) (2017) · Cochrane | RR 3.23 [2.15, 4.86] | 4 studies · 1213 participants | Moderate |